Patents by Inventor Bindu Santhamma

Bindu Santhamma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10738075
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 11, 2020
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES
    Publication number: 20200087340
    Abstract: Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.
    Type: Application
    Filed: September 13, 2019
    Publication date: March 19, 2020
    Inventors: Hareesh Nair, Bindu Santhamma, Gulzar Ahmed, Klaus Nickisch
  • NOVEL CYTOTOXIC AGENTS THAT PREFERENTIALLY TARGET LEUKEMIA INHIBITORY FACTOR (LIF) FOR THE TREATMENT OF MALIGNANCIES AND AS NEW CONTRACEPTIVE AGENTS
    Publication number: 20190153018
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 23, 2019
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Pro-drug forming compounds
    Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10053485
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • PROGESTERONE ANTAGONISTS
    Publication number: 20180155386
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 7, 2018
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
    Patent number: 9850273
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • PRO-DRUG FORMING COMPOUNDS
    Publication number: 20170349624
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 7, 2017
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Pro-drug forming compounds
    Patent number: 9745338
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 29, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • NOVEL CYTOTOXIC AGENTS THAT PREFERENTIALLY TARGET LEUKEMIA INHIBITORY FACTOR (LIF) FOR THE TREATMENT OF MALIGNANCIES AND AS NEW CONTRACEPTIVE AGENTS
    Publication number: 20160279145
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • COMBINATION OF ESTROGENS PLUS ANTIPROGESTINS WITH SIGNIFICANT PARTIAL AGONISTIC EFFECT AS AN EFFECTIVE TREATMENT OF MENOPAUSAL SYMPTOMS AND FOR PREVENTION OF THE OCCURRENCE OF BREAST CANCER
    Publication number: 20160159852
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Imidazolyl progesterone antagonists
    Patent number: 9096641
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 4, 2015
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma
  • PRO-DRUG FORMING COMPOUNDS
    Publication number: 20150018322
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • IMIDAZOLYL PROGESTERONE ANTAGONISTS
    Publication number: 20140364600
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 11, 2014
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma
  • METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL
    Publication number: 20130123523
    Abstract: Described herein is a process for the synthesis of etonogestrel and desogestrel and intermediates used to form etonogestrel and desogestrel.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 16, 2013
    Inventors: Klaus Nickisch, Bindu Santhamma
  • PROGESTERONE ANTAGONISTS
    Publication number: 20130029953
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 31, 2013
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Methods for the preparation of drospirenone
    Patent number: 8334375
    Abstract: Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: December 18, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Kirk Acosta, Bindu Santhamma
  • METHODS FOR THE PREPARATION OF DROSPIRENONE
    Publication number: 20100261896
    Abstract: Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
    Type: Application
    Filed: April 1, 2010
    Publication date: October 14, 2010
    Inventors: Klaus Nickisch, Kirk Acosta, Bindu Santhamma